<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004916</url>
  </required_header>
  <id_info>
    <org_study_id>NU 98H2</org_study_id>
    <secondary_id>NU-98H2</secondary_id>
    <secondary_id>NCI-G00-1711</secondary_id>
    <nct_id>NCT00004916</nct_id>
  </id_info>
  <brief_title>Ifosfamide, Teniposide, and Paclitaxel in Treating Patients With Relapsed Non-Hodgkin's Lymphoma</brief_title>
  <official_title>Phase I/II Study of Mesna, Ifosfamide, Teniposide and Weekly Taxol (MITTen) in Relapsed Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing&#xD;
      so they stop growing or die. Combining more than one drug may kill more cancer cells.&#xD;
&#xD;
      PURPOSE: Phase I/II trial to study the effectiveness of ifosfamide, teniposide, and&#xD;
      paclitaxel in treating patients who have relapsed non-Hodgkin's lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the toxicities associated with the combination of ifosfamide, teniposide, and&#xD;
           weekly paclitaxel in patients with relapsed non-Hodgkin's lymphoma.&#xD;
&#xD;
        -  Evaluate response rate and time to disease progression in these patients treated with&#xD;
           this regimen.&#xD;
&#xD;
      OUTLINE: This is a dose escalation study of teniposide. Patients are stratified according to&#xD;
      whether they proceed to stem cell transplant or not.&#xD;
&#xD;
      Patients receive ifosfamide IV over 1-2 hours on days 1-3 every 3 weeks, teniposide IV over 2&#xD;
      hours on day 1 every 3 weeks, and paclitaxel IV over 1 hour weekly. Patients who are not&#xD;
      candidates for stem cell transplant continue treatment for 120 days in the absence of disease&#xD;
      progression or unacceptable toxicity. Patients proceeding to stem cell transplant continue&#xD;
      treatment for 36 days. Peripheral blood stem cells (PBSC) may be harvested at this time if&#xD;
      autologous transplant is planned. Transplant patients may then continue with chemotherapy or&#xD;
      proceed to autologous or allogeneic PBSC transplant.&#xD;
&#xD;
      Cohorts of 3-5 patients receive escalating doses of teniposide until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 3&#xD;
      of 5 patients experience dose limiting toxicities.&#xD;
&#xD;
      Patients are followed every 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 15-50 patients will be accrued for this study within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 1999</start_date>
  <completion_date type="Actual">October 2002</completion_date>
  <primary_completion_date type="Actual">October 2002</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ifosfamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>teniposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed intermediate or high grade non-Hodgkin's lymphoma&#xD;
&#xD;
               -  No lymphoblastic or small cleaved lymphoma&#xD;
&#xD;
          -  Progressive disease following doxorubicin based chemotherapy&#xD;
&#xD;
               -  No more than 2 prior treatment regimens&#xD;
&#xD;
          -  Measurable or evaluable disease NOTE: A new classification scheme for adult&#xD;
             non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of &quot;indolent&quot; or&#xD;
             &quot;aggressive&quot; lymphoma will replace the former terminology of &quot;low&quot;, &quot;intermediate&quot;, or&#xD;
             &quot;high&quot; grade lymphoma. However, this protocol uses the former terminology.&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 2 times upper limit of normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No significant cardiac disease&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No active or uncontrolled second malignancy&#xD;
&#xD;
          -  No other medical problems that would preclude therapy&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Prior stem cell transplant allowed&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leo I. Gordon, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Robert H. Lurie Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Robert H. Lurie Comprehensive Cancer Center, Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-3013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <study_first_submitted>March 7, 2000</study_first_submitted>
  <study_first_submitted_qc>May 13, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2003</study_first_posted>
  <disposition_first_submitted>July 1, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>July 1, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 14, 2011</disposition_first_posted>
  <last_update_submitted>May 31, 2012</last_update_submitted>
  <last_update_submitted_qc>May 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Teniposide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

